Literature DB >> 28848873

The COPD Pipeline XXX.

Nicholas Gross1.   

Abstract

Keywords:  AZD5069; Apremilast; CHF6001; GSK256066; Glassia; Mepolizumab; Neutrophil Imaging; Phosphodiesterase inhibitors; RPL554; Tacholiquine; Tetomilast; a triple MDI; delivery devices; flu vaccine

Year:  2015        PMID： 28848873      PMCID： PMC5559133          DOI： 10.15326/jcopdf.3.1.2015.0181

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN： 2372-952X


× No keyword cloud information.
  11 in total

1.  Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial.

Authors:  David J Lederer; Matthew N Bartels; Neil W Schluger; Frances Brogan; Patricia Jellen; Byron M Thomashow; Steven M Kawut
Journal:  COPD       Date:  2012-02-23       Impact factor: 2.409

2.  GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.

Authors:  Cathy J Tralau-Stewart; Richard A Williamson; Anthony T Nials; Michele Gascoigne; John Dawson; Graham J Hart; Anthony D R Angell; Yemisi E Solanke; Fiona S Lucas; Joanne Wiseman; Peter Ward; Lisa E Ranshaw; Richard G Knowles
Journal:  J Pharmacol Exp Ther       Date:  2011-01-04       Impact factor: 4.030

3.  The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.

Authors:  A M Kirsten; K Förster; E Radeczky; A Linnhoff; B Balint; H Watz; H Wray; L Salkeld; M Cullberg; B Larsson
Journal:  Pulm Pharmacol Ther       Date:  2015-02-11       Impact factor: 3.410

Review 4.  New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences.

Authors:  Vincent Ninane; Jan Vandevoorde; Didier Cataldo; Eric Derom; Giuseppe Liistro; Evert Munghen; Rudi Peché; Marc Schlesser; Geert Verleden; Walter Vincken
Journal:  Respir Med       Date:  2015-09-30       Impact factor: 3.415

5.  The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.

Authors:  Stipo Jurcevic; Charles Humfrey; Mohib Uddin; Steve Warrington; Bengt Larsson; Christina Keen
Journal:  Br J Clin Pharmacol       Date:  2015-10-02       Impact factor: 4.335

6.  Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.

Authors:  Andrew R Goudie; Brian J Lipworth; Pippa J Hopkinson; Li Wei; Allan D Struthers
Journal:  Lancet Respir Med       Date:  2014-03-05       Impact factor: 30.700

7.  Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.

Authors:  R Siva; R H Green; C E Brightling; M Shelley; B Hargadon; S McKenna; W Monteiro; M Berry; D Parker; A J Wardlaw; I D Pavord
Journal:  Eur Respir J       Date:  2007-02-14       Impact factor: 16.671

8.  CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.

Authors:  Nadia Moretto; Paola Caruso; Raffaella Bosco; Gessica Marchini; Fiorella Pastore; Elisabetta Armani; Gabriele Amari; Andrea Rizzi; Eleonora Ghidini; Renato De Fanti; Carmelida Capaldi; Laura Carzaniga; Emilio Hirsch; Carola Buccellati; Angelo Sala; Chiara Carnini; Riccardo Patacchini; Maurizio Delcanale; Maurizio Civelli; Gino Villetti; Fabrizio Facchinetti
Journal:  J Pharmacol Exp Ther       Date:  2015-01-09       Impact factor: 4.030

9.  Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD.

Authors:  Henrik Watz; Sunil J Mistry; Aili L Lazaar
Journal:  Pulm Pharmacol Ther       Date:  2013-05-21       Impact factor: 3.410

10.  Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.

Authors:  Lui G Franciosi; Zuzana Diamant; Katharine H Banner; Rob Zuiker; Nicoletta Morelli; Ingrid M C Kamerling; Marieke L de Kam; Jacobus Burggraaf; Adam F Cohen; Mario Cazzola; Luigino Calzetta; Dave Singh; Domenico Spina; Michael J A Walker; Clive P Page
Journal:  Lancet Respir Med       Date:  2013-10-25       Impact factor: 30.700
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.